EUthyroid2: the Next Step Towards the Elimination of Iodine Deficiency and Preventable Iodine-related Disorders in Europe
The Next Step Towards the Elimination of Iodine Deficiency and Preventable Iodine-related Disorders in Europe
EUthyroid
1,000 participants
Nov 18, 2024
INTERVENTIONAL
Conditions
Summary
In EUthyroid2 intervention measures are to be developed, implemented in ambulatory care settings and evaluated to effectively raise awareness for the risks of iodine deficiency among young women (18-24 years) in three European countries (Norway, Poland, UK) as well as Bangladesh and Pakistan. A cluster-randomized controlled trial with three points of measurements will be applied in each participating country. The intervention will be adapted to the different contextual characteristics of the implementation sites. A process evaluation with a convergent parallel mixed methods design will be conducted. For this, participants and healthcare professionals will be surveyed and semi-structured interviews will be carried out.
Eligibility
Inclusion Criteria4
- non-pregnant Female
- Age 18-24 years at the time point of recruitment
- Attending the specified settings
- Sufficient language skills to understand the study information, informed consent and the questionnaire
Exclusion Criteria3
- Having a thyroid disease
- Pregnancy at the timepoint of recruitment and during the intervention period
- Lactation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The intervention consist of an educational intervention which will educate the young women on the importance of iodine, the consequences of iodine deficiency, dietary iodine sources and the iodine in pregnancy. The educational intervention consist of four intervention components: an iodine feedback tool, and educational iodine conversation with a healthcare professional, an iodine factsheet and an iodine video. The healthcare professionals who carry out the educational conversation will receive a specially designed training program.
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06769009